Deutsche Bank Aktiengesellschaft Has Lowered Expectations for Sarepta Therapeutics (NASDAQ:SRPT) Stock Price

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) had its target price dropped by stock analysts at Deutsche Bank Aktiengesellschaft from $124.00 to $99.00 in a note issued to investors on Wednesday,Benzinga reports. The firm presently has a "hold" rating on the biotechnology company's stock. Deutsche Bank Aktiengesellschaft's target price indicates a potential upside of 33.60% from the stock's current price.

Several other research analysts also recently issued reports on the stock. Scotiabank started coverage on shares of Sarepta Therapeutics in a research note on Friday, March 7th. They issued a "sector perform" rating and a $105.00 target price on the stock. StockNews.com downgraded shares of Sarepta Therapeutics from a "buy" rating to a "hold" rating in a research note on Wednesday, November 20th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $163.00 target price on shares of Sarepta Therapeutics in a research note on Tuesday, March 18th. Royal Bank of Canada dropped their target price on shares of Sarepta Therapeutics from $165.00 to $161.00 and set an "outperform" rating on the stock in a research note on Thursday, February 27th. Finally, Piper Sandler dropped their target price on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an "overweight" rating on the stock in a research note on Wednesday, November 27th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $167.41.

Remove Ads

Sarepta Therapeutics Stock Up 0.9 %

NASDAQ:SRPT traded up $0.65 during mid-day trading on Wednesday, hitting $74.10. 2,591,321 shares of the company's stock were exchanged, compared to its average volume of 1,218,291. Sarepta Therapeutics has a one year low of $73.05 and a one year high of $173.25. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The business has a fifty day moving average price of $107.19 and a 200 day moving average price of $117.88. The company has a market cap of $7.19 billion, a PE ratio of 59.28 and a beta of 0.79.

Insider Buying and Selling at Sarepta Therapeutics

In other news, Director Claude Nicaise sold 2,491 shares of the stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the sale, the director now directly owns 27,812 shares of the company's stock, valued at $2,771,187.68. This represents a 8.22 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 7.70% of the stock is owned by corporate insiders.

Institutional Trading of Sarepta Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of SRPT. Sumitomo Mitsui Trust Group Inc. increased its stake in shares of Sarepta Therapeutics by 21.4% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,700 shares of the biotechnology company's stock worth $212,000 after purchasing an additional 300 shares in the last quarter. Oppenheimer Asset Management Inc. increased its stake in shares of Sarepta Therapeutics by 3.4% in the third quarter. Oppenheimer Asset Management Inc. now owns 4,457 shares of the biotechnology company's stock worth $557,000 after purchasing an additional 145 shares in the last quarter. Huntington National Bank increased its stake in shares of Sarepta Therapeutics by 150.9% in the third quarter. Huntington National Bank now owns 291 shares of the biotechnology company's stock worth $36,000 after purchasing an additional 175 shares in the last quarter. CIBC Asset Management Inc increased its stake in shares of Sarepta Therapeutics by 3.3% in the third quarter. CIBC Asset Management Inc now owns 2,712 shares of the biotechnology company's stock worth $339,000 after purchasing an additional 86 shares in the last quarter. Finally, Commerce Bank increased its stake in shares of Sarepta Therapeutics by 15.7% in the third quarter. Commerce Bank now owns 2,016 shares of the biotechnology company's stock worth $252,000 after purchasing an additional 274 shares in the last quarter. 86.68% of the stock is owned by hedge funds and other institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.